Giant cell tumors of soft tissue (GCT-ST) are rare low-grade neoplasms that were at one time thought to represent the soft tissue counterparts of GCT of bone (GCT-B) but are now known to lack the H3F3 mutations characteristic of osseous GCT. We present six distinctive giant cell-rich soft tissue neoplasms that expressed keratins and carried a recurrent HMGA2-NCOR2 gene fusion. Patients were five females and one male aged 14-60 years (median, 29). All presented with superficial (subcutaneous) masses that were removed by conservative marginal (3) or wide (2) local excision. The tumors originated in the upper extremity (2), lower extremity (2), head/neck (1), and trunk (1). Five patients with follow-up (median, 21 months; range, 14-168) remained disease-free. Grossly, all tumors were well-demarcated but not encapsulated with variable lobulation. Histologically, they were composed of bland plump epithelioid or ovoid to spindled mononuclear cells admixed with evenly distributed multinucleated osteoclast-type giant cells. Foci of stromal hemorrhage and hemosiderin were seen in all cases. The mitotic activity ranged from 2 to 14/10 high power fields (median: 10). Foci of necrosis and vascular invasion were seen in one case each. The mononuclear cells were immunoreactive with the AE1/AE3 keratin cocktail and less frequently/less diffusely for K7 and K19 but lacked expression of other lineage-associated markers. RNA-based next-generation sequencing revealed an HMGA2-NCOR2 fusion in all tumors. None of the keratin-negative conventional GCT-ST showed the HMGA2-NCOR2 fusion (0/7). Metaplastic bone (4/9) and SATB2 expression (3/4) were frequent in keratin-negative conventional GCT-ST but were lacking in keratin-positive HMGA2-NCOR2 fusion-positive tumors. The distinctive immunophenotype and genotype of these tumors strongly suggest that they represent a discrete entity, differing from conventional GCT-ST and other osteoclast-rich morphologic mimics. Their natural history appears favorable, although a study of additional cases and longer follow-up are warranted.

Bioptical Laboratory Ltd Plzen Czech Republic

Department of Laboratory Medicine and Pathology Mayo Clinic Rochester MN USA

Department of Nephropathology Institute of Pathology Friedrich Alexander University Erlangen Nürnberg Erlangen Germany

Department of Oncological and Experimental Pathology Cancer Institute Brno Czech Republic

Department of Pathology Charles University Faculty of Medicine in Plzen Plzen Czech Republic

Department of Pathology Faculty of Medicine Hacettepe University Ankara Turkey

Department of Translational Research University of Pisa School of Medicine Pisa Italy

Institute of Pathology Friedrich Alexander University Erlangen Nürnberg University Hospital of Erlangen Erlangen Germany

See more in PubMed

Flanagan AM, Larousserie F, O´Donnell PG, Yoshida A. Giant cell tumour of bone. In: WHO Classification of Tumours, Soft Tissue and Bone Tumours, 5th Edition, International Agency for Research on Cancer, Lyon, France, Vol. 3. 2020. p. 440–46.

Oliveira AM, Lee JC. Giant cell tumour of soft tissue. In: In: WHO Classification of Tumours, Soft Tissue and Bone Tumours, 5th Edition, Vol. 3. 2020. p. 141–42.

Chow LT. Giant cell rich osteosarcoma revisited-diagnostic criteria and histopathologic patterns, Ki67, CDK4, and MDM2 expression, changes in response to bisphosphonate and denosumab treatment. Virchows Arch. 2016;468:741–55. doi: 10.1007/s00428-016-1926-9. PubMed DOI

Mentzel T, Calonje E, Fletcher CD. Leiomyosarcoma with prominent osteoclast-like giant cells. Analysis of eight cases closely mimicking the so-called giant cell variant of malignant fibrous histiocytoma. Am J Surg Pathol. 1994;18:258–65. doi: 10.1097/00000478-199403000-00005. PubMed DOI

Rekhi B, Verma A, Jambhekar NA, Menon S, Laskar S, Merchant N, et al. Osteoclast-rich, proximal-type epithelioid sarcoma: clinicopathologic features of 3 unusual cases expanding the histomorphological spectrum. Ann Diagn Pathol. 2016;21:39–43. doi: 10.1016/j.anndiagpath.2015.12.003. PubMed DOI

Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, et al. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45:1479–82. doi: 10.1038/ng.2814. PubMed DOI PMC

Presneau N, Baumhoer D, Behjati S, Pillay N, Tarpey P, Campbell PJ, et al. Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res. 2015;1:113–23. doi: 10.1002/cjp2.13. PubMed DOI PMC

Lüke J, von Baer A, Schreiber J, Lübbehüsen C, Breining T, Mellert K, et al. H3F3A mutation in giant cell tumour of the bone is detected by immunohistochemistry using a monoclonal antibody against the G34W mutated site of the histone H3.3 variant. Histopathology. 2017;71:125–33. doi: 10.1111/his.13190. PubMed DOI

Righi A, Mancini I, Gambarotti M, Picci P, Gamberi G, Marraccini C, et al. Histone 3.3 mutations in giant cell tumor and giant cell-rich sarcomas of bone. Hum Pathol. 2017;68:128–35. doi: 10.1016/j.humpath.2017.08.033. PubMed DOI

Yamamoto H, Iwasaki T, Yamada Y, Matsumoto Y, Otsuka H, Yoshimoto M, et al. Diagnostic utility of histone H3.3 G34W, G34R, and G34V mutant-specific antibodies for giant cell tumors of bone. Hum Pathol. 2018;73:41–50. doi: 10.1016/j.humpath.2017.11.020. PubMed DOI

Nielsen GP, Fletcher CD, Smith MA, Rybak L, Rosenberg AE. Soft tissue aneurysmal bone cyst: a clinicopathologic study of five cases. Am J Surg Pathol. 2002;26:64–9. doi: 10.1097/00000478-200201000-00007. PubMed DOI

Enzinger FM, Zhang RY. Plexiform fibrohistiocytic tumor presenting in children and young adults. An analysis of 65 cases. Am J Surg Pathol. 1988;12:818–26. doi: 10.1097/00000478-198811000-00002. PubMed DOI

Moosavi C, Jha P, Fanburg-Smith JC. An update on plexiform fibrohistiocytic tumor and addition of 66 new cases from the Armed Forces Institute of Pathology, in honor of Franz M. Enzinger, MD. Ann Diagn Pathol. 2007;11:313–9. doi: 10.1016/j.anndiagpath.2007.01.003. PubMed DOI

Guccion JG, Enzinger FM. Malignant giant cell tumor of soft parts. An analysis of 32 cases. Cancer. 1972;29:1518–29. doi: 10.1002/1097-0142(197206)29:6<1518::AID-CNCR2820290616>3.0.CO;2-#. PubMed DOI

Angervall L, Hagmar B, Kindblom LG, Merck C. Malignant giant cell tumor of soft tissues: a clinicopathologic, cytologic, ultrastructural, angiographic, and microangiographic study. Cancer. 1981;47:736–47. doi: 10.1002/1097-0142(19810215)47:4<736::AID-CNCR2820470419>3.0.CO;2-Q. PubMed DOI

Folpe AL, Morris RJ, Weiss SW. Soft tissue giant cell tumor of low malignant potential: a proposal for the reclassification of malignant giant cell tumor of soft parts. Mod Pathol. 1999;12:894–902. PubMed

Oliveira AM, Dei Tos AP, Fletcher CD, Nascimento AG. Primary giant cell tumor of soft tissues: a study of 22 cases. Am J Surg Pathol. 2000;24:248–56. doi: 10.1097/00000478-200002000-00011. PubMed DOI

O’Connell JX, Wehrli BM, Nielsen GP, Rosenberg AE. Giant cell tumors of soft tissue: a clinicopathologic study of 18 benign and malignant tumors. Am J Surg Pathol. 2000;24:386–95. doi: 10.1097/00000478-200003000-00007. PubMed DOI

Lee JC, Liang CW, Fletcher CD. Giant cell tumor of soft tissue is genetically distinct from its bone counterpart. Mod Pathol. 2017;30:728–33. doi: 10.1038/modpathol.2016.236. PubMed DOI

Mancini I, Righi A, Gambarotti M, Picci P, Dei Tos AP, Billings SD, et al. Phenotypic and molecular differences between giant-cell tumour of soft tissue and its bone counterpart. Histopathology. 2017;71:453–60. doi: 10.1111/his.13249. PubMed DOI

Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5:R80. doi: 10.1186/gb-2004-5-10-r80. PubMed DOI PMC

R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria: 2020. https://www.R-project.org/.

Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. PubMed PMC

Warnes GR, Bolker B, Bonebakker L, Gentleman R, Huber W, Liaw A, et al. gplots: Various R Programming Tools for Plotting Data. R package version 3.1.0. 2020. https://CRAN.R-project.org/package=gplots.

Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nat Protoc. 2009;4:44–57. doi: 10.1038/nprot.2008.211. PubMed DOI

Bieg M, Moskalev EA, Will R, Hebele S, Schwarzbach M, Schmeck S, et al. Bieg M, Moskalev EA, Will R, Hebele S, Schwarzbach M, Schmeck S. et al. Gene expression in Solitary Fibrous Tumors (SFTs) correlates with anatomical localization and NAB2-STAT6 gene fusion variants. 2021. 10.1016/j.ajpath.2020.12.015. PubMed

de Lange K, de Boer EN, Bosga A, Alimohamed MZ, Johansson LF, Mulder AB, et al. Targeted RNA-sequencing enables detection of relevant translocations and single nucleotide variants and provides a method for classification of hematological malignancies-RANKING. Clin Chem. 2021 doi: 10.1093/clinchem/hvaa221. PubMed DOI

Maggiani F, Forsyth R, Hogendoorn PC, Krenacs T, Athanasou NA. The immunophenotype of osteoclasts and macrophage polykaryons. J Clin Pathol. 2011;64:701–5. doi: 10.1136/jcp.2011.090852. PubMed DOI

de la Roza G. p63 expression in giant cell-containing lesions of bone and soft tissue. Arch Pathol Lab Med. 2011;135:776–9. doi: 10.5858/2010-0291-OA.1. PubMed DOI

Reeves R, Beckerbauer L. HMGI/Y proteins: flexible regulators of transcription and chromatin structure”. Biochim Biophys Acta. 2001;519:13–29. doi: 10.1016/S0167-4781(01)00215-9. PubMed DOI

Dahlén A, Mertens F, Rydholm A, Brosjö O, Wejde J, Mandahl N, et al. Fusion, disruption, and expression of HMGA2 in bone and soft tissue chondromas. Mod Pathol. 2003;16:1132–40. doi: 10.1097/01.MP.0000092954.42656.94. PubMed DOI

Stenman G. Fusion oncogenes in salivary gland tumors: molecular and clinical consequences. Head Neck Pathol. 2013;7:S12–9. doi: 10.1007/s12105-013-0462-z. PubMed DOI PMC

Bianchini L, Birtwisle L, Saâda E, Bazin A, Long E, Roussel JF, et al. Identification of PPAP2B as a novel recurrent translocation partner gene of HMGA2 in lipomas. Genes Chromosomes Cancer. 2013;52:580–90. doi: 10.1002/gcc.22055. PubMed DOI

Panagopoulos I, Gorunova L, Bjerkehagen B, Lobmaier I, Heim S. The recurrent chromosomal translocation t(12;18)(q14~15;q12~21) causes the fusion gene HMGA2-SETBP1 and HMGA2 expression in lipoma and osteochondrolipoma. Int J Oncol. 2015;47:884–90. doi: 10.3892/ijo.2015.3099. PubMed DOI PMC

Brahmi M, Alberti L, Tirode F, Karanian M, Eberst L, Pissaloux D, et al. Complete response to CSF1R inhibitor in a translocation variant of teno-synovial giant cell tumor without genomic alteration of the CSF1 gene. Ann Oncol. 2018;29:1488–9. doi: 10.1093/annonc/mdy129. PubMed DOI

Chen JD, Evans RM. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 1995;377:454–7. doi: 10.1038/377454a0. PubMed DOI

Sande S, Privalsky ML. Identification of TRACs (T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors. Mol Endocrinol. 1996;10:813–25. PubMed

Fritchie KJ, Torres-Mora J, Inwards C, Thway K, Vaiyapuri S, Jackson R, et al. Xanthogranulomatous epithelial tumor: report of 6 cases of a novel, potentially deceptive lesion with a predilection for young women. Mod Pathol. 2020;33:1889–95. doi: 10.1038/s41379-020-0562-8. PubMed DOI

Conventional (bone-type) giant cell tumor of the larynx: the first case with proven H3-3A: c.103G >T (p.Gly35Trp) mutation